Genetix Biotherapeutics Inc.

What Genetix Biotherapeutics Inc. does

Genetix Biotherapeutics Inc. (formerly bluebird bio) is a commercial-stage biotechnology company headquartered in Somerville, Massachusetts, developing and commercializing ex vivo lentiviral vector (LVV) gene addition therapies for severe rare genetic diseases. The company's proprietary platform collects patients' own hematopoietic stem cells, modifies them outside the body using the BB305 lentiviral vector to add functional copies of affected genes, and reinfuses them as a one-time treatment. Genetix markets three FDA-approved autologous gene therapies: LYFGENIA (lovotibeglogene autotemcel) for sickle cell disease in patients 12 and older, ZYNTEGLO (betibeglogene autotemcel) for transfusion-dependent beta-thalassemia, and SKYSONA (elivaldogene autotemcel) for cerebral adrenoleukodystrophy (CALD).

The business model is built on one-time administered gene therapies priced at $2-3 million per patient, with revenue recognized upon infusion. Genetix distributes through a network of 70 Qualified Treatment Centers (QTCs) in the U.S. — the largest network for hemoglobinopathy gene therapies — supported by Orsini Healthcare as specialty pharmacy partner. The company also generates licensing and royalty revenue through an exclusive partnership with SPIMACO for commercialization in Saudi Arabia and the broader Middle East, with technology transfer fees and double-digit royalties on sales. Manufacturing is outsourced to a CDMO consortium including Lonza (Houston facility for ZYNTEGLO), Minaris, and MilliporeSigma.

Following its February 2025 acquisition by Carlyle and SK Capital for approximately $29 million — down from a peak valuation above $10 billion — the company was taken private, appointed a new leadership team led by CEO David Meek, and rebranded to Genetix Biotherapeutics in September 2025. As of late 2025, 392 patients had been enrolled, 216 had initiated cell collection, and 115 had completed treatment across LYFGENIA and ZYNTEGLO, with over 90% of eligible patients having commercial or Medicaid coverage access. The company achieved its first profitable quarter in 2025 and is targeting first full-year profitability in 2026, supported by a planned doubling of commercial manufacturing capacity by mid-2026.

Name

Genetix Biotherapeutics Inc.

Legal name

Genetix Biotherapeutics, Inc.

Website

https://genetixbiotx.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

101–250 employees

Short description

Genetix Biotherapeutics is a commercial-stage gene therapy company marketing three FDA-approved ex vivo lentiviral vector treatments — LYFGENIA, ZYNTEGLO, and SKYSONA — for sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy, delivered through 70 U.S. Qualified Treatment Centers and specialty pharmacy partners.

Ownership category

akta.pro rank

Product category

Gene Therapy / Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Lentiviral Vector Gene Therapy Developers (HLAAACAB)

akta.pro secondary industries

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Neurology/CNS Gene Therapies (HLAAACAH), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Gene therapy products
• Cell therapy platforms
• Rare disease treatments
• Hematology therapies
• Biopharmaceutical products

Headquarters

HQ city

Somerville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Gene Therapy Product Sales: One-time administered gene therapies priced at $2-3 million per patient treatment. Revenue recognized upon patient infusion. The company reported over 100 patients treated in 2025, achieving its first ever profitable quarter.
2. Technology Transfer Fees and Royalties: Ongoing technology transfer fee payments and double-digit royalties on sales from the SPIMACO partnership for commercialization of LYFGENIA and ZYNTEGLO in Saudi Arabia and the broader Middle East region.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Genetix Biotherapeutics develops, manufactures, and commercializes three FDA-approved ex vivo lentiviral vector gene addition therapies (LYFGENIA, ZYNTEGLO, and SKYSONA) for severe rare genetic diseases. The therapies are one-time administered autologous treatments that modify a patient's own hematopoietic stem cells outside the body to add functional copies of the affected gene, addressing sickle cell disease, transfusion-dependent beta-thalassemia, and cerebral adrenoleukodystrophy.

Differentiator

Problem solved

Functional benefit

Products and services

• LYFGENIA (lovotibeglogene autotemcel) One-time gene therapy for sickle cell disease patients 12 years and older with a history of vaso-occlusive events; reduces or eliminates VOEs by adding functional copies of a modified β-globin gene to the patient's own stem cells.
• ZYNTEGLO (betibeglogene autotemcel) One-time gene therapy for adult and pediatric patients with transfusion-dependent beta-thalassemia; eliminates or reduces the need for ongoing regular blood transfusions by adding functional β-globin genes to the patient's own stem cells.
• SKYSONA (elivaldogene autotemcel) One-time gene therapy for boys with early, active cerebral adrenoleukodystrophy (CALD); treats the underlying genetic cause of this rare neurodegenerative disease to slow the progression of brain damage.

Quantifiable outcome

• Over 90% of eligible patients with commercial or Medicaid coverage have access to LYFGENIA and ZYNTEGLO
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and major.

• SPIMACO (Saudi Pharmaceutical Industries and Medical Appliances Corporation)coreChannel Partner/ Reseller/ Distributor · 23 June 2026Exclusive collaboration and license agreement for development, commercialization, and localized manufacturing of LYFGENIA and ZYNTEGLO in Saudi Arabia and broader Middle East. SPIMACO and its subsidiary SPIMACO Bio will be responsible for market authorization, development, commercialization, and establishing localized manufacturing capabilities. Genetix receives ongoing technology transfer fee payments and a double-digit royalty on sales.
• LonzacoreTechnology or Integration · 9 March 2026Extended commercial manufacturing agreement for ZYNTEGLO at Lonza's Houston facility. Collaboration began in 2013 and enabled ZYNTEGLO's commercial approval in 2022. Expanded to include capacity scaling for additional Genetix therapies in response to rapidly growing patient demand.
• MilliporeSigmamajorTechnology or Integration · 2 March 2026Partnership with MilliporeSigma (the U.S. and Canada business of Merck KGaA, Darmstadt, Germany) as one of three CDMO partners strengthening commercial manufacturing capacity. Company is doubling manufacturing capacity through partnerships with Minaris, Lonza, and MilliporeSigma.
• Orsini HealthcarecoreChannel Partner/ Reseller/ Distributor · 26 February 2026Selected specialty pharmacy partner for distribution of LYFGENIA, ZYNTEGLO, and SKYSONA. Orsini's Cell and Gene Therapy Center of Excellence now supports 12 gene therapies total.
• MinariscoreTechnology or Integration · 12 January 2026Expanded manufacturing partnership to increase commercial-scale production of LYFGENIA. Collaboration significantly increases manufacturing capacity through process and operational improvements. Minaris invested in infrastructure, talent, and capacity to support long-term commercial supply.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• uniQure: Develops AAV-based gene therapies for hemophilia B and other rare diseases. Comparable in scale and stage, focused on commercial-stage rare disease gene therapy with similar manufacturing and reimbursement challenges.
• Krystal Biotech: Markets Vyjuvek, a topical gene therapy for dystrophic epidermolysis bullosa. Comparable rare disease gene therapy commercial-stage company with growing revenue and profitability trajectory.
• Vertex Pharmaceuticals: Markets Casgevy (exa-cel), a CRISPR-based gene therapy for sickle cell disease that directly competes with Genetix's LYFGENIA in the same patient population. Both target severe hemoglobinopathies with one-time curative intent.
• CRISPR Therapeutics: Co-developer of Casgevy with Vertex, using ex vivo CRISPR gene editing in autologous hematopoietic stem cells. Closely analogous ex vivo gene modification platform competing in the same sickle cell and beta-thalassemia indications.
• BioMarin Pharmaceutical: Markets Roctavian, an AAV gene therapy for hemophilia A. Comparable rare disease gene therapy commercial model with similar pricing, distribution, and payer negotiation dynamics.

Broad incumbents

• Pfizer: Large biopharma with gene therapy assets (incl. hemophilia programs via Spark) and global manufacturing/sales infrastructure for high-cost rare disease therapies. Brian Riley, Genetix's CTO, held prior roles at Beam, a Pfizer-partnered company.
• Sarepta Therapeutics: Markets Elevidys, a gene therapy for Duchenne muscular dystrophy. Comparable commercial-stage rare disease gene therapy with similar high-price, one-time treatment model and payer access dynamics.
• Novartis: Markets Zolgensma, the leading-selling gene therapy ($1.23B in 2025). Broad biopharma incumbent with established gene therapy infrastructure and reimbursement capabilities for rare disease one-time treatments.

Emerging players

• Beam Therapeutics: Develops base editing gene therapies for sickle cell disease and beta-thalassemia — directly overlapping indications with LYFGENIA and ZYNTEGLO, representing next-generation competitive threat.
• Editas Medicine: Clinical-stage CRISPR gene editing company with programs in sickle cell disease. Overlapping therapeutic area and platform technology creating future competitive dynamics in hemoglobinopathies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/genetix_biotx
• YouTubeyoutube.com/@genetix_biotx
• LinkedInlinkedin.com/company/genetix-biotherapeutics
• Instagraminstagram.com/genetix_biotx

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds18 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genetix Biotherapeutics Inc.